Positive Airway Pressure Therapy Predicts Lower Mortality and Major Adverse Cardiovascular Events Incidence in Medicare Beneficiaries with Obstructive Sleep Apnoea

Diego R Mazzotti, Ph.D.*[1,2], Lemuel R. Waitman, Ph.D.[3], Jennifer Miller, Ph.D., APRN-NP[4], ACNPC-AG, Krishna M. Sundar, M.D.[5], Nancy H. Stewart, D.O., M.S.[2], David Gozal, M.D., M.B.A., Ph.D.[6], Xing Song, Ph.D.[3], Greater Plains Collaborative.

[1]Division of Medical Informatics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
[2]Division of Medical Informatics, Department of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS, USA
[3]Department of Health Management and Informatics, School of Medicine, University of Missouri-Columbia, MO, USA
[4]College of Nursing, University of Nebraska Medical Center, Omaha, NE, USA
[5]Department Division of Pulmonary and Critical Care Medicine, Department of Medicine University of Utah, Salt Lake City, UT, USA
[6]Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA

*Corresponding author
Diego R. Mazzotti, Ph.D.
Division of Medical Informatics, Department of Internal Medicine
University of Kansas Medical Center
3901 Rainbow Boulevard
Kansas City, KS, 66160
Mailstop 3065
Office: +1 (913) 588-8223 | Fax: +1 (913) 588-4880 | Email: droblesmazzotti@kumc.edu

Text abstract and keywords

Background: Obesity is associated with obstructive sleep apnoea (OSA) and cardiovascular

risk. Positive airway pressure (PAP) is the first line treatment for OSA, but evidence on its

beneficial effect on major adverse cardiovascular events (MACE) prevention is limited. Using

claims data, the effects of PAP on mortality and incidence of MACE among Medicare

beneficiaries with OSA were examined.

Methods: A cohort of beneficiaries (>65 years) with ≥5 years of consecutive enrolment to

Medicare and ≥2 distinct OSA claims was defined from multi-state, state-wide, multi-year (2011-

2017) Medicare fee-for-service claims data. Evidence of PAP initiation and utilisation was based

on PAP claims after OSA diagnosis. MACE was defined as a composite of myocardial

infarction, heart failure, stroke, or coronary revascularisation. Doubly robust Cox proportional

hazards models with inverse probability of treatment weights estimated treatment effects

controlling for sociodemographic and clinical factors.

Results: Among 225,132 beneficiaries with OSA (median age 74 years; 45.3% women; median

follow-up 3 years), those with evidence of PAP initiation (50.1%) had significantly lower all-

cause mortality (HR [95%CI]: 0.57 [0.56-0.59]) and MACE incidence risk (0.90 [0.88-0.92]).

Higher quartiles of annual PAP claims were progressively associated with lower mortality (Q2:

0.80 [0.75-0.86], Q3: 0.68 [0.64-0.72], Q4: 0.65 [0.61-0.70]) and MACE incidence risk (Q2: 0.91

[0.86-0.97], Q3: 0.87 [0.82-0.91], Q4: 0.85 [0.80-0.90]).

Conclusion: PAP utilisation was associated with lower all-cause mortality and MACE incidence

among Medicare beneficiaries with OSA. Results might inform trials assessing the importance

of OSA therapy towards minimising cardiovascular risk and mortality in older adults.

Keywords: obstructive sleep apnoea, positive airway pressure, Center for Medicare and

Medicaid Services, cardiovascular disease, inverse probability of treatment weights.

Introduction

Obesity is a chronic condition with significant public health burden[1], affecting 40% of

adults in the U.S.[2] and accounting for millions of cardiovascular (CV) disease deaths every

year[3]. There is greater attention about the importance of adequate sleep habits[4] and its relation

to cardiometabolic risk[5,6]. Obstructive sleep apnoea (OSA) is a highly prevalent disorder

contributing to these associations, with population rates of 9%-37% in men and 4-50% in

women[7], affecting nearly 1 billion people worldwide[8]. OSA becomes more prevalent with age[9,10]

and obesity[11], and is associated with coronary heart disease, stroke, and CV mortality[12,13]. The

CV risk due to OSA is greater among those with excessive sleepiness[14,15], worse nocturnal

hypoxemia[16], and differential heart rate responses to respiratory events[17]. Thus, there is

increasing attention on therapies that may modify CV risk for primary and secondary

prevention[5,6,18] through targeting sleep disordered breathing[19].

Positive airway pressure (PAP) is the first line of therapy for moderate-severe OSA.

Despite epidemiological studies strongly suggesting that OSA is a modifiable CV risk factor[20-26],

a meta-analysis of randomised controlled trials (RCTs) failed to demonstrate that PAP prevents

CV outcomes[27]. Studies have shown that patient selection and treatment adherence may

explain some of the negative results[28,29]. These challenges are intensified by the lack of large,

equitable, and multi-centric pragmatic studies assessing the effectiveness of PAP on improving

CV risk. Such studies are expensive and time-consuming, leading to recruitment and retention

challenges, and delayed policy changes[31,32]. Whether long-term PAP therapy prevents CV

disease in a clinical population is a critical question that remains unanswered.

Insurance claims data allow the design of observational studies that complement RCTs,

by adopting causal inference methods[29,33,34]. When robustly applied, they have the potential to

characterise the effect of OSA therapies in representative clinical settings[35]. A study on a

French nationwide claims database found that continuous PAP (CPAP) therapy termination was

associated with all-cause mortality and incidence of heart failure[36]. In the U.S., Centers for

Medicare & Medicaid Services (CMS) beneficiaries represent a large population of older adults

with access to healthcare coverage. Studies exploring a 5% sample of randomly selected

beneficiaries found that those with OSA had higher healthcare utilisation when compared to

matched controls[37]. Moreover, those adherent to CPAP based on Durable Medical Equipment

(DME) claims were found to have reduced risk of stroke[38] and healthcare expenses among

those with pre-existing CV diseases[39]. However, a major limitation is the reliance only on a

sample of beneficiaries, which might represent challenges characterising the effects of PAP on

the incidence of individual CV diseases with accuracy. State-wide Medicare claims, particularly

within underserved states in the U.S., might reflect a broader representation of individuals with

OSA and provide more generalisable effect estimates.

In this study, we aimed to determine the effect of PAP utilisation on all-cause mortality

and incidence of MACE and its components among Medicare beneficiaries across 11 states in

the Central U.S. By leveraging a robust causal inference design, we determined the average

treatment effect of PAP initiation on the risk of incident MACE and mortality. Next, we

established clinically relevant cut-offs of PAP utilisation based on DME claims over the first year

after PAP initiation to determine PAP utilisation exposure groups. We demonstrate that these

groups are differentially associated with incident MACE and mortality among older adults.

Finally, we provide effect estimates of PAP exposure groups stratified by relevant

sociodemographic and clinical factors.

Methods

Additional details are presented in the ***Supplemental materials***.

Study cohort

Medicare beneficiaries (>65 years) with ≥5 years of consecutive enrolment to part A and

B, and ≥2 distinct OSA claims were collected from multi-state, state-wide, multi-year (2011-

2017) Medicare fee-for-service claims data. State-level Medicare claims data were originally

obtained as part of the Greater Plains Collaborative Reusable Observable Unified Study

Environment (GROUSE)[40], with a catchment area across 11 states in the Central U.S. The

study protocol has been approved by Institutional Review Boards at each institution. The study

cohort was defined based on a validated EHR algorithm to identify participants with OSA[41] (see

Supplemental Table 1). We further required >1 year enrolment with Medicare before their first

OSA claim, to better capture newly diagnosed OSA and complete PAP utilisation history. For

the analysis of incident MACE, we further excluded beneficiaries with history of MACE prior to

their OSA diagnosis date.

Study design

This is an observational, retrospective analysis of state-wide Medicare claims data. We

proposed two complementary causal inference designs to estimate the average treatment effect

(ATE) of PAP initiation (**Figure 1**) and PAP utilisation exposure groups (**Figure 2**). For the PAP

initiation analyses, prescription time-distribution matching[42] was used to identify the "time zero"

(exposure assignment, covariate determination, and start of follow-up) for the group that did not

initiate PAP (*pseudo landmark date*, **Figure 1**), matched on the distribution of the time from

diagnosis and start of PAP therapy in the group that initiated PAP (*landmark T*, **Figure 1**). For

the analysis of PAP utilisation exposure groups, we included beneficiaries that have been

enrolled and have not experienced events at the 1-year mark since their PAP initiation date.

Exposure groups were defined based on the distribution of claim counts during this first year of

PAP utilisation and "time zero" was the date of the first anniversary of PAP initiation (**Figure 2**).

PAP utilisation definitions

Evidence of PAP initiation was based on the first PAP initiation claim after OSA

diagnosis (*Supplemental methods*). PAP utilisation exposure groups were used as surrogate

measures of PAP adherence. We explored different surrogates based on the total count of PAP

claims during first year of utilisation. Prior studies have suggested that a greater number of DME

claims, such as mask refills, correlates with objective adherence based on hours of use[43]. A

comprehensive comparison of all methods is presented in the *Supplemental methods* and

informed the selection of the quartile-based PAP utilisation exposure group definition, which

was then used in our primary analysis.

Study Outcomes

We assessed two primary outcomes: all-cause mortality and incidence of MACE. All-

cause mortality was obtained by identifying date of death provided in the Medicare beneficiary

summary file. MACE was defined as a composite of first occurrence of myocardial infarction

(MI), heart failure (HF), stroke or coronary revascularisation, identified by diagnostic and

procedure codes (**Supplemental Table 1**). Secondary analyses using each component of

MACE as outcomes are also presented.

Covariates

We included the following covariates: age, sex, race (White, Black, American Indian,

Asian, Other), socioeconomic status, prior history of type 2 diabetes, hypertension, obesity,

MACE (only in models assessing all-cause mortality), chronic obstructive pulmonary disease

(COPD), hypersomnia, and insomnia (see **Supplemental Table 1** for definitions).

Statistical analyses

Sociodemographic characteristics and clinical history were described between PAP

initiation exposure groups using counts and percentages for categorical data and median and

interquartile range for continuous data. Univariate associations between sociodemographic and

clinical history variables with PAP initiation exposure groups were performed using chi-squared

tests. We used Kaplan-Meier survival analyses and log-rank tests to compare survival curves

between PAP initiation exposure groups for MACE and all-cause mortality. We assessed the

proportional hazards assumption by assessing scaled Schoenfeld residuals, which did not find

strong evidence of violation. We implemented a causal inference framework to determine the

effect of PAP initiation or PAP utilisation exposure groups on the outcomes of interest (all-cause

mortality and MACE. Specific details are presented in the ***Supplemental methods***. Briefly, we

derived propensity scores (PS) based on PAP initiation or utilisation, and then calculated

weights that were used in fully adjusted weighted Cox regression models assessing the effect of

PAP initiation or PAP utilisation exposure groups on the outcomes of interest, representing

causal estimate of the ATE derived from a doubly robust estimator. This framework was applied

to our primary analyses, as well as to secondary analyses assessing individual components of

MACE. Results of stratified analysis by sociodemographic and clinical characteristics are also

presented. We determined statistical significance based on Bonferroni-corrected thresholds of

p<0.025 (2 primary outcomes) and provide E-values to assess the strength of association a

potential unmeasured confounder would need to express to nullify observed associations[45].

Results

Sample characterisation

Our sample included 225,132 eligible Medicare beneficiaries with evidence of OSA

diagnosis (median [Q1, Q3] age 74 [71, 79] years; 45.3% women; median [Q1, Q3] follow-up 3

[1.9, 4.7] years). **Figure 3** shows the study flowchart. Among eligible participants, 112,703

(50.1%) had evidence of PAP initiation. **Table 1** shows the sample characteristics according to

PAP initiation groups. Participants that have initiated PAP were younger, more likely to be men

and White, more likely to have been diagnosed with hypersomnia and less likely to be

1 diagnosed with COPD, type 2 diabetes, hypertension, and to have had a first MACE at OSA

2 diagnosis. Overall, 5-year cumulative mortality rate was 18.2% (based on total N=225,132) and

3 5-year cumulative MACE incidence was 43.6% (based on those without MACE at baseline,

4 N=139,663). When stratified by PAP initiation exposure groups, those who initiated PAP had a

5 5-year cumulative mortality rate and cumulative MACE incidence of 13.1% and 41.4%

6 respectively. Those who did not initiate PAP had a 5-year incidence rates of mortality and

7 MACE event of 23.5% and 46.2%, respectively (p<0.001 for both).

9 *PAP initiation is associated with greater survival and MACE-free probability*

10   Kaplan-Meier survival curves for all-cause mortality and MACE, according to PAP

11 initiation exposure groups are presented in **Figure 4**. Log-rank test indicates significant

12 differences in all-cause mortality and MACE-free survival probabilities (p<0.001), with

13 participants that have initiated PAP presenting greater survival than those without.

15 *PAP initiation is independently associated with lower mortality and lower incidence of MACE*

16   Results of doubly robust Cox proportional hazards models are presented in **Figure 5,**

17 **Stratification: None**. Patients with evidence of PAP initiation had significantly lower all-cause

18 mortality risk (HR [95%CI] = 0.57 [0.56-0.59]; p<0.001) and lower MACE incidence risk (0.90

19 [0.88-0.92]; p<0.001) when compared to those without evidence of initiating PAP. The risk ratio

20 of an unmeasured confounder (E-value) would need to be 2.90 to explain away the effect of

21 PAP initiation on mortality, and 1.36 to explain away the effect on MACE.

22   Analyses of secondary outcomes (MI, HF, stroke, and coronary revascularisation) are

23 presented in **Supplemental Figure 1**. OSA patients with evidence of PAP initiation had

24 significantly lower incidence risk of MI (0.84 [0.81-0.87]; p<0.001; E-value: 1.67), HF (0.91

25 [0.89-0.93]; p<0.001; E-value: 1.43), and stroke (0.84 [0.81-0.87]; p<0.001; E-value: 1.67). No

26 association with incident coronary revascularisation was observed (0.96 [0.92-1.00]; p=0.055).

1   Next, we investigated whether the effect of PAP initiation was consistent across

2  subgroups of sociodemographic and clinical factors. Results of primary outcomes are presented

3  in **Figure 5** and of secondary outcomes are presented in **Supplemental Figure 1**. We observed

4  that effect estimates regarding all-cause mortality are consistent across subgroups, with

5  significantly lower risk among those that initiated PAP across all strata, and key differences in

6  certain subgroups. We observed stronger protective effects of PAP initiation among those 70

7  years or older (70-74 years: 0.58 [0.56-0.60]; 75-79 years: 0.56 [0.54-0.58]; 80+: 0.55 [0.54-

8  0.57], as compared to those 65-69 years (0.69 [0.65-0.73]). Similar trends were observed

9  among women (0.55 [0.54-0.57]) as compared to men (0.59 [0.57-0.60]), those with lower social

10  economic status (0.55 [0.54-0.57]) as compared to those with higher (0.59 [0.57-0.60]), those

11  with evidence of obesity diagnosis (0.52 [0.50-0.53]) as compared to those without (0.60 [0.59-

12  0.61]), those with evidence of history of MACE (0.55 [0.54-0.57]) as compared to those without

13  (0.61 [0.59-0.63]), and those without evidence of hypersomnia (0.57 [0.56-0.58]) as compared

14  to those with (0.69 [0.62-0.76]).

15   Regarding incidence of MACE, we only observed significant PAP initiation effects among

16  those 70 years or older (70-74 years: 0.89 [0.87-0.91]; 75-79 years: 0.89 [0.87-0.92]; 80+: 0.87

17  [0.85-0.89], as compared to those 65-69 years (0.97 [0.94-1.00]). We also observed slightly

18  stronger protective effects of PAP initiation among women (0.88 [0.86-0.90]) as compared to

19  men (0.92 [0.90-0.93]), those with lower social economic status (0.85 [0.83-0.87]) as compared

20  to those with higher (0.92 [0.91-0.94]), those with evidence of obesity diagnosis (0.86 [0.83-

21  0.88]) as compared to those without (0.91 [0.90-0.93]), and those with evidence of COPD

22  diagnosis (0.87 [0.85-0.90]) as compared to those without (0.91 [0.90-0.92]).

23   Stratified analyses regarding secondary outcomes (MACE components) consistently

24  showed significantly lower incidence of MI, HF, and stroke across all subgroups of

25  sociodemographic and clinical factors, with no consistent differences regarding coronary

26  revascularisation procedures (**Supplemental Figure 1**). Important differences were observed

for certain subgroups. Regarding MI, strongest beneficial effects of PAP initiation were observed

among those with 70-74 years (0.79 [0.76-0.83]), those with lower social economic status (0.78

[0.75-0.81]), and those with evidence of hypertension diagnosis (0.82 [0.80-0.95]). Regarding

HF, strongest beneficial effects of PAP initiation were observed in those 70 years or older (70-

75 years: 0.92 [0.89-0.94]; 75-79 years: 0.89 [0.86-0.92]; 80+ years: 0.86 [0.83-0.88]), those

with lower social economic status (0.85 [0.83-0.87]), and those with evidence of obesity

diagnosis (0.87 [0.84-0.90]). Regarding stroke, strongest beneficial effects of PAP initiation were

observed among those with 70-74 years (0.83 [0.80-0.87]), women (0.81 [0.78-0.84]), and

among those with evidence of type 2 diabetes diagnosis (0.81 [0.78-0.84]). Regarding coronary

revascularisation, strongest beneficial effects of PAP initiation were observed among those with

70-74 years (0.90 [0.86-0.94]).

Determination of first year PAP utilisation exposure groups

To inform our proposed analysis assessing the effect of PAP utilisation exposure groups,

we first observed the distribution of total PAP claims per patient at the end of first year of PAP

utilisation (**Supplemental Figure 2**). PAP claim counts showed a bimodal distribution,

suggesting two utilisation patterns were more prevalent: a mode on 4 claims and a mode on 15

claims, which may be suggestive of CMS PAP reimbursement models[46] and may correlate with

PAP adherence[47,48]. Because Medicare claims databases do not include PAP adherence

tracking, we explored different PAP exposure group definitions (see *PAP utilisation definitions*

and **Supplemental Figure 3**) to determine relevant cut-offs in the distribution of PAP claims.

We further assessed associations between different PAP exposure group definitions and our

primary and secondary outcomes. In general, a greater count of PAP claims during the first year

was progressively associated with lower all-cause mortality and lower MACE incidence risk

(**Supplemental Figure 4**), as well as lower incident MI, HF, and stroke (**Supplemental Figure**

5), reaching a plateau after approximately 14-16 claims. When using the numeric count of PAP

claims as our exposure, each additional PAP claim was significantly associated with lower

hazards of all-cause mortality (0.97 [0.96-0.97]), MACE (0.99 [0.99-0.99]), MI (0.99 [0.98-0.99]),

HF (0.99 [0.98-0.99]) and stroke (0.98 [0.97-0.98]), but not with coronary revascularisations

(1.00 [0.99-1.01]). To address the non-linearity of the associations between PAP claim counts

and outcomes, we performed spline extrapolation analyses and estimated the HR as a function

of PAP claim counts (**Supplemental Figure 6**). Results suggest HR estimates are the highest

(e.g., greater hazards) around 4-9 PAP claims and lowest at 18-20 PAP claims across all study

outcomes. Taken together, these exploratory analyses helped to inform us that using a *quartile-*

based definition of PAP exposure groups based on claim counts (Q1: 1 to 11 claims; Q2: 12 to

14 claims; Q3: 15 to 16 claims; and Q4: >16 claims) provided a realistic representation of PAP

utilisation patterns that demonstrated clinically relevant variation in incident outcome risk.

Therefore, we focused the description of the following results based on this definition.

Greater PAP utilisation is progressively associated with lower risk of mortality and MACE

Results of doubly robust Cox proportional hazards models assessing the effect of PAP

utilisation exposure groups based on quartiles of PAP claim counts on all-cause mortality and

incidence of MACE are presented in **Figure 6** (among all participants [Stratification: None] and

stratified by sociodemographic characteristics) and **Figure 7** (stratified by comorbidities), and

results for secondary outcomes are presented in **Supplemental Figure 7 and 8**. Among

patients with OSA and with evidence of PAP utilisation in their first year of therapy, higher

quartiles of claim counts (i.e., higher PAP utilisation) were progressively associated with lower

all-cause mortality (Q2: 0.80 [0.75-0.86], Q3: 0.68 [0.64-0.72], Q4: 0.65 [0.61-0.70]) and lower

MACE incidence (Q2: 0.91 [0.86-0.97], Q3: 0.87 [0.82-0.91], Q4: 0.85 [0.80-0.90]), when

compared to those with ≤11 PAP claims in their first year. Similar results were observed for

secondary outcomes, with lower MI incidence risk on Q3 (0.85 [0.76-0.96]) and Q4 (0.81 [0.72-

0.92]), lower HF incidence risk (Q2: 0.89 [0.82-0.95], Q3: 0.83 [0.78-0.89], Q4: 0.84 [0.78-0.90])

and lower stroke incidence risk (Q2: 0.81 [0.73-0.91], Q3: 0.82 [0.75-0.91], Q4: 0.74 [0.66-

0.82]). No evidence of association with incident coronary revascularisation was observed

(**Supplemental Figure 7**).

4   Analyses stratified by sociodemographic characteristics (**Figure 6** and **Supplemental**

Figure 7) and comorbidities (**Figure 7** and **Supplemental Figure 8**) were consistent overall,

supporting the protective effects of higher PAP claim counts against all-cause mortality and

incident MACE across several strata. Exceptions include certain race groups and those with

positive history of hypersomnia, likely due to the limited sample size of subgroups resulting in

wide confidence intervals and less accurate estimates. Regarding all-cause mortality, key

differences across strata include stronger protective effects of higher PAP utilisation among

those with 65-69 years, and those with evidence of insomnia. Regarding MACE, stronger

protective effects of higher PAP utilisation were observed among those with 65-69 years,

women, those with lower socioeconomic status, those without history of hypertension, and those

without evidence of insomnia. Regarding MI, stronger protective effects of higher PAP utilisation

were observed among those with 70-74 years and >80 years, women, those with lower

socioeconomic status, those without evidence of obesity, those with history of type 2 diabetes

and those without evidence of insomnia. Regarding HF, stronger protective effects of higher

PAP utilisation were observed among those with 65-69 years, men (except for >16 claims),

those with lower socioeconomic status, those without history of hypertension, and those without

evidence of insomnia. Regarding stroke, protective effects of higher PAP utilisation were

observed among those with 65-69 years, women, those with lower socioeconomic status (>16

claims only), those with evidence of COPD (>16 claims only), and those with history of

hypertension. Finally, regarding coronary revascularisation procedures, protective effects of

higher PAP utilisation were only observed among those with 65-69 years, women (except 15-16

claims), and those with lower socioeconomic status. Effects estimates and confidence intervals

are shown in **Figures 6** and **7**, and **Supplemental Figures 7** and **8**.

Discussion

This study provided a systematic assessment of the effects of PAP initiation and

utilisation on MACE and mortality among older adults that are Medicare beneficiaries across 11

states in the U.S. Our main findings suggest significant associations between claims-based PAP

initiation and utilisation and lower all-cause mortality and incidence of MACE. Associations of

PAP initiation and utilisation were also significant for MACE components, with consistent effects

on MI, HF, and stroke. We observed that PAP initiation effects were stronger in women and in

those 70 years or older, with lower socioeconomic status and with clinical comorbidities. Higher

PAP utilisation exposure groups were progressively associated with lower incidence of primary

(i.e., mortality, MACE) and secondary (i.e., MI, HF, stroke) outcomes, with consistent effects in

stratified analysis, but with particularly stronger beneficial effects among those between 65-69

years, women, and those with lower socioeconomic status. We used a robust causal inference

framework to minimise immortal time bias and provided more reliable estimates of treatment

effects. Results from this observational study might inform future trials assessing the importance

of OSA therapy initiation and maintenance towards minimising CV risk and mortality in older

adults.

Extensive epidemiological evidence suggests that moderate-severe OSA is associated

with hypertension[49-51], stroke[26], atrial fibrillation[52] MI[53], and CV mortality[54]. Several mechanisms

may explain the relationship between OSA and CV diseases, including sympathetic activation,

endothelial dysfunction, oxidative stress, systemic inflammation, cardiac remodelling due to

hypoxemia, intrathoracic pressure swings and changes in blood pressure[55]. These overlapping

mechanisms indicate that therapies targeting OSA are likely to be beneficial towards CV

disease prevention. RCTs have established that PAP improves daytime symptoms, mood, and

quality of life[56,57], and reduces systolic and diastolic blood pressure[49], especially in patients with

resistant hypertension[51]. PAP therapy has positive effects on long-term survival in patients with

ischemic stroke and moderate-severe OSA[58] and it has been associated with lower rate of fatal

and non-fatal CV events over a 10-year follow-up[53].

Despite this consistent evidence, recent RCTs[59-61] investigating the effect of CPAP on

different fatal and non-fatal CV events were negative[27]. A careful investigation of the limitations

in these trials[29] has suggested that patient selection and treatment adherence may have played

an important role on explaining differences between RCTs and observational studies. In fact,

only 20% of patients seeking care in sleep clinics would be eligible to participate in these

RCTs[30]. Many patients present with excessive daytime sleepiness, which was an important

exclusion criterion in these trials, due to the ethical reason of randomising patients that are

excessively sleepy into control arms[29]. However, we[14,62] and others[15,63] have demonstrated this

subgroup is at increased risk for incident CV diseases. These observations suggest that

alternative approaches using causal inference in well-designed observational studies could

provide more generalisable evidence towards the role of PAP therapy on CV outcomes risk.

Exploring 'real-world data' approaches using robust statistical methods that minimise

biases and confounding issues that are inherent to observational studies may help inform

evidence generation in a more timely and cost-effective manner. The success of these

approaches has been demonstrated by the current investigation, as it provided relevant and

generalisable evidence about the beneficial effects of PAP initiation and utilisation in a defined

population of older adults in the U.S.. It has also been demonstrated by recent studies exploring

the role of CPAP on risk of mortality, HF[36], stroke[38], reduced health-care utilisation[64] and related

expenses among those with pre-existing CV diseases[39], including HF with reduced ejection

fraction[65]. In the context of a recently published report from the AHRQ suggesting a lack of

strong evidence supporting the role of PAP on long-term CV outcomes[66], these studies are

fundamental to fill this evidence gap.

Our study has identified important associations within subgroups. Notably, we observed

greater beneficial effects of PAP initiation on mortality and MACE among older adults ≥70 years,

suggesting that primary CV prevention among those with newly diagnosed OSA at older ages could be beneficial. However, these results are conflicting with a 3-month RCT of CPAP therapy among elderly adults >70 years with moderate-severe OSA, which did not find significant effects on blood pressure levels or neurocognitive tests, although significant improvements in sleepiness were observed[67]. A secondary analysis of this trial, only among those >80 years, did not find significant effects on sleepiness[68]. Among those that initiated PAP therapy, our study found greater beneficial effects of PAP utilisation in those that are 65-69 years. Differences may be explained by length of follow-up and study design considerations. Future trials assessing the role of PAP therapy on the health of older adults using longer follow-up times are warranted. We also observed stronger PAP initiation and greater utilisation effects on mortality and MACE among women, in agreement with prior studies, particularly post-menopause[56]. It is likely that women are subjected to stronger acute detrimental effects of OSA following menopause, and therefore might experience stronger therapeutic effects. Women with OSA are also more likely to have comorbid metabolic conditions[69]. However, little is known about sex differences in PAP treatment responses[70], particularly at older ages. Patients with lower socioeconomic status may be less receptive to receiving PAP therapy[71] and report poorer treatment adherence[72]. Yet, our results demonstrate that those with low-income subsidy and dual Medicare/Medicaid eligibility have greater benefit of PAP against mortality and MACE. These results highlight opportunities to implement care programs designed to minimise health disparities, as recently proposed[73]. Our study also identified stronger effects of PAP initiation among those with comorbid conditions such as obesity, COPD, and type 2 diabetes. It is likely that these subgroups are at a greater underlying risk with the added comorbid impact[12,74-76], and therefore therapy benefit might be greater. Importantly, subgroups with evidence for comorbidities might also represent patients at highest risk for early termination of CPAP[77], which suggests that efforts to support therapy continuation might be beneficial particularly for these patients. We also found stronger beneficial effects of PAP initiation among those without evidence of hypersomnia, which contradicts the

well-established relationship between excessive daytime sleepiness and increased CV risk

among those with OSA[14,15,62,63]. However, granular measures of excessive daytime sleepiness

might provide a more robust phenotype when compared to claims for hypersomnia. Only ~6% of

our study cohort had evidence of hypersomnia, which suggests it might not capture all patients

with the excessively sleepy phenotype. In summary, these results might help guide future RCTs

assessing the role of PAP initiation and/or strategies to increase PAP adherence among higher-

risk subgroups.

This study utilised state-wide Medicare claims data to determine the effects of PAP

initiation and utilisation on outcomes. While we acknowledge that objective definitions of PAP

adherence and efficacy are still preferred to estimate exposure to PAP, telemonitoring data has

only become available in recent years[78]. Prior studies have investigated similar PAP exposure

definitions in a nationwide claims database in France[36,77] and within 5% Medicare beneficiaries

samples in the U.S.[37-39,79], and reported consistent results as with objective PAP adherence

data[64,65]. From an epidemiologic perspective, state-wide claims databases cover a large

proportion of the older adult demographic and offer a scalable approach to identify those likely

to be exposed to PAP independently of vendor or telemonitoring capabilities, thus maximising

generalisability. A single-site study comparing objective adherence based on hours of use found

that mask refill claims positively correlated with PAP utilisation[43]. To provide further information

about PAP utilisation based on claims, our study presented a detailed assessment of different

PAP utilisation exposure group definitions. We observed a bimodal distribution of PAP claim

counts within the first year since PAP initiation, which is suggestive of recognised CMS

reimbursement models [46]. CMS reimburses PAP therapy among eligible beneficiaries in monthly

instalments; when a patient does not meet the eligibility criteria for continued therapy at the third

month of utilisation, the device is not reimbursed, and no further claims will be identified. We

speculate that the first mode of the distribution (4 claims) may represent patients that did not

meet the CMS criteria for adherence and therefore may present lower overall PAP utilisation

during their first year. Similarly, the second mode (15 claims) may represent patients that have

demonstrated early adherence and continued to use PAP throughout the year. Our results are

consistent with this definition, as it suggests that greater number of PAP claims are associated

with greater beneficial outcomes. Therefore, while large scale multisite studies predicting short-

and long-term objective PAP adherence using claims data are still needed, the definitions used

in our study seem to capture relevant clinical outcomes regarding PAP utilisation.

Our study has important limitations. First, our cohort identification approach was based

on ICD codes, available through a Medicare claims database, thus preventing characterisation

of disease severity based on the apnoea-hypopnea index (AHI) or other novel physiological

traits that have been recently demonstrated to be important for CV risk stratification, such as

hypoxic burden[16] and heart rate responses to events[17]. However, we used an algorithm

validated in different clinical sites that demonstrated excellent predictive performance[41],

suggesting that our cohort definition reliably captured individuals with OSA. Second, as

previously discussed, our claims-based PAP utilisation definition may not accurately represent

more objective definitions of PAP use. However, hours of use (often used as the only exposure

when telemonitoring data is available) may not be the only determinant of PAP efficacy, as other

factors such as proportion of protected sleep time (e.g., how many hours sleep on efficacious

PAP relative to total sleep time), efficacy of therapy reflected by the optimal pressure, minimal

leak, and minimal residual AHI, and even timing of PAP utilisation during the night (e.g., early

morning termination of therapy might induce more severe rapid eye movement sleep AHI

reducing overall PAP efficacy[80,81]), might be more important predictors of successful therapy,

and are yet to be consistently assessed in telemonitoring studies. We encourage that PAP

vendors expand academic-industry partnerships towards facilitating privacy-preserving linkage

of PAP telemonitoring databases with more granular information from EHR, claims, patient

reported outcomes and wearables. Such approaches will be fundamental in future studies

aimed at determining the effects of PAP therapy on both short- and long-term clinical outcomes.

Third, our covariate definition was based only on claims data, and lack granular information

about other relevant confounders such as body mass index, blood pressure, and laboratory

measurements that are predictive of CV risk. Moreover, other important factors such as diet,

physical activity, and healthy adherer behaviours[82] were not available and could explain some of

the observed effects. To mitigate this limitation, we provide E-values as a guide to understand

the impact of a potential unmeasured confounders in our reported associations. Results suggest

that unmeasured confounders with effects (in the risk ratio scale) as large as 2.90 for all-cause

mortality and 1.36 for MACE would have to be observed, after adjustment for other covariates,

to explain away associations with our primary outcomes. Finally, the present study focuses on a

population of older adults that are Medicare beneficiaries in the Central U.S., and extrapolation

of effect estimates to other demographics cannot be made. In one hand, studies in mid-life

adults would provide important insights about OSA natural history and early prevention of CV

outcomes. On the other hand, our study is generalisable to a very large proportion of older

adults, as >95% of those >65 years in the Unites States are enrolled in Medicare. There is also

greater confidence in the ascertainment of outcomes.

In conclusion, PAP utilisation based on claims was associated with lower all-cause

mortality and MACE incidence (including MI, HF, and stroke) among Medicare beneficiaries >65

years. Results support the hypothesis that PAP has beneficial effects against mortality and CV

diseases. This study has the potential to inform future trials assessing the importance of OSA

therapy initiation and maintenance towards minimising adverse health outcomes in older adults

leading to longer and healthier lives. These results may also inform strategies to improve

adherence and efficacy of PAP therapy there are patient-specific, towards personalised sleep

medicine.

Acknowledgements

The authors would like to acknowledge the technical and scientific resources and support from

the Greater Plains Collaborative team members, as well as all Medicare beneficiaries whose

data were contributing to this investigation.

Funding

The study was funded by the American Heart Association (20CDA35310360), Patient-Centered

Outcomes Research Institute (RI-CRN-2020-003-IC); NIH CTSA NCATS Frontiers: University of

Kansas Clinical and Translational Science Institute (UL1TR002366); Tier 2 grant, University of

Missouri.

Conflict of interest statement

Dr. Krishna Sundar was a past advisory board member for Resmed Inc. and is the co-founder of

Hypnoscure LLC through the University of Utah Technology Commercialization Office All other

authors declared no conflicts of interest.

Data availability statement

The data underlying this article cannot be shared publicly to protect the privacy of individuals

that participated in the study, as stipulated by each institution of the Greater Plains

Collaborative. There are established processes for interested investigators to collaborate with

the Greater Plains Collaborative research network, that can be accessed via this URL:

https://gpcnetwork.org/.

Notes

Greater Plains Collaborative: Sravani Chandaka, Kelechi (KayCee) Anuforo, Lav Patel, Daryl

Budine, Nathan Hensel, Siddharth Satyakam, Sharla Smith, Dennis Ridenour, Cheryl Jernigan,

Carol Early, Kyle Stephens, Kathy Jurius, Abbey Sidebottom, Cassandra Rodgers, Hong Zhong,

Vino Raj, Victor Melendez, Angie Hare, Roman Melamed, Curtis Anderson, Thomas Schouweile, Christine Roering, Philip Payne, Snehil Gupta, John Newland, Albert Lai, Joyce Balls-Berry, Janine Parham, Evin Fritschle, Shanelle Cripps, Kirk Knowlton, Channing Hansen, Erna Serezlic, Benjamin Horne, Jeff VanWormer, Judith Hase, Janet Southworth, Eric Larose, Mary Davis, Laurel Hoeth, Sandy Strey, Brad Taylor, Kris Osinski, April Haverty, Alex Stoddard, Sarah Cornell, Phoenix Do, Lucy Bailey, Beth McDonough, Betsy Chrischilles, Ryan Carnahan, Brian Gryzlak, Gi-Yung Ryu, Katrina Oaklander, Pastor Bruce Hanson, Brad McDowell, Jarrod Field, Abu Mosa, Sasha Lawson, Jim McClay, Soliman Islam, Vasanthi Mandhadi, Kim Kimminau, Dennis Ridenour, Jeff Ordway, Bill Stephens, Russ Waitman, Deandra Cassone, Xiaofan Niu, Lisa Royse, Vyshnavi Paka, Lori Wilcox, Janelle Greening, Carol Geary, Goutham Viswanathan, Jim Svoboda, Jim Campbel, Frances (Annette) Wolfe, Haddy Bah, Todd Bjorklund, Jackson Barlocker, Josh Spuh, Louisa Stark, Mike Strong, Otolose Fahina Tavake-Pas, Rachel Hess, Jacob Kean, Sarah Mumford, Ainsley Huffman, Annie Risenmay, Olivia Ellsmore, Lissa Persson, Kayla Torres Morales, Sandi Stanford, Mahanaz Syed, Rae Schofield, Meredith Zozus, Brian Shukwit, Matthew Decaro, Natalia Heredia, Charles Miller, Alice Robinson, Elmer Bernstam, Fatima Ashraf, Shiby Antony, Juliet Fong Zechner, Philip Reeder, Cindy Kao, Kate Wilkinson, Tracy Greer, Alice Robinson, Lindsay Cowell

References

1.   Powell-Wiley TM, Poirier P, Burke LE*, et al.* Obesity and Cardiovascular Disease: A
Scientific Statement From the American Heart Association. *Circulation* 2021;**143**. doi:
10.1161/cir.0000000000000973
2.   Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity
Among Adults in the United States, 2005 to 2014. *Jama* 2016;**315**. doi:
10.1001/jama.2016.6458
3.   The GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195
Countries over 25 Years. *New England Journal of Medicine* 2017;**377**:13-27. doi:
10.1056/NEJMoa1614362
4.   Hall WL. The emerging importance of tackling sleep–diet interactions in lifestyle
interventions for weight management. *British Journal of Nutrition* 2022;**128**:561-568. doi:
10.1017/s000711452200160x
5.   Tsao CW, Aday AW, Almarzooq ZI*, et al.* Heart Disease and Stroke Statistics-2022
Update: A Report From the American Heart Association. *Circulation* 2022;**145**:e153-e639. doi:
10.1161/CIR.0000000000001052
6.   Lloyd-Jones DM, Allen NB, Anderson CAM*, et al.* Life's Essential 8: Updating and
Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential
Advisory From the American Heart Association. *Circulation* 2022;**146**. doi:
10.1161/cir.0000000000001078
7.   Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the
population-a review on the epidemiology of sleep apnea. *J Thorac Dis* 2015;**7**:1311-1322. doi:
10.3978/j.issn.2072-1439.2015.06.11
8.   Benjafield AV, Ayas NT, Eastwood PR*, et al.* Estimation of the global prevalence and
burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med* 2019;**7**:687-
698. doi: 10.1016/S2213-2600(19)30198-5
9.   Punjabi NM. The Epidemiology of Adult Obstructive Sleep Apnea. *Proceedings of the*
American Thoracic Society 2008;**5**:136-143. doi: 10.1513/pats.200709-155MG
10.   Mirer AG, Young T, Palta M*, et al.* Sleep-disordered breathing and the menopausal
transition among participants in the Sleep in Midlife Women Study. *Menopause* 2017;**24**:157-
162. doi: 10.1097/gme.0000000000000744
11.   Jehan S, Zizi F, Pandi-Perumal SR*, et al.* Obstructive Sleep Apnea and Obesity:
Implications for Public Health. *Sleep Med Disord* 2017;**1**. doi:
12.   Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive Sleep Apnea. *Journal*
of the American College of Cardiology 2013;**62**:569-576. doi: 10.1016/j.jacc.2013.05.045
13.   Monahan K, Redline S. Role of obstructive sleep apnea in cardiovascular disease.
Current Opinion in Cardiology 2011;**26**:541-547. doi: 10.1097/HCO.0b013e32834b806a
14.   Mazzotti DR, Keenan BT, Lim DC*, et al.* Symptom Subtypes of Obstructive Sleep Apnea
Predict Incidence of Cardiovascular Outcomes. *Am J Respir Crit Care Med* 2019;**200**:493-506.
doi: 10.1164/rccm.201808-1509OC
15.   Labarca G, Dreyse J, Salas C, Letelier F, Jorquera J. A Validation Study of Four
Different Cluster Analyses of OSA and the Incidence of Cardiovascular Mortality in a Hispanic
Population. *Chest* 2021;**160**:2266-2274. doi: 10.1016/j.chest.2021.06.047
16.   Azarbarzin A, Sands SA, Stone KL*, et al.* The hypoxic burden of sleep apnoea predicts
cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the
Sleep Heart Health Study. *European Heart Journal* 2019;**40**:1149-1157. doi:
10.1093/eurheartj/ehy624
17.   Azarbarzin A, Sands SA, Younes M*, et al.* The Sleep Apnea–Specific Pulse-Rate
Response Predicts Cardiovascular Morbidity and Mortality. *American Journal of Respiratory and*
Critical Care Medicine 2021;**203**:1546-1555. doi: 10.1164/rccm.202010-3900OC

18. Mazzotti DR, Drager LF. Opportunities for Cardiovascular Benefits in Treating Obstructive Sleep Apnea in the Secondary Prevention Scenario. *Am J Respir Crit Care Med* 2020;**202**:1622-1624. doi: 10.1164/rccm.202007-2805ED

19. Yeghiazarians Y, Jneid H, Tietjens JR*, et al.* Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation* 2021;**144**:e56-e67. doi: 10.1161/CIR.0000000000000988

20. Marin JM, Carrizo SJ, Vicente E, Agusti AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet (London, England)* 2005;**365**:1046-1053. doi: 10.1016/S0140-6736(05)71141-7

21. Gottlieb DJ, Yenokyan G, Newman AB*, et al.* Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. *Circulation* 2010;**122**:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801

22. Shahar E, Whitney CW, Redline S*, et al.* Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *American Journal of Respiratory and Critical Care Medicine* 2001;**163**:19-25. doi: 10.1164/ajrccm.163.1.2001008

23. Somers VK, White DP, Amin R*, et al.* Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). *Circulation* 2008;**118**:1080-1111. doi: 10.1161/CIRCULATIONAHA.107.189375

24. Nieto FJ, Young TB, Lind BK*, et al.* Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. *JAMA* 2000;**283**:1829-1836. doi:

25. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *The New England Journal of Medicine* 2000;**342**:1378-1384. doi: 10.1056/NEJM200005113421901

26. Li M, Hou W-S, Zhang X-W, Tang Z-Y. Obstructive sleep apnea and risk of stroke: a meta-analysis of prospective studies. *International Journal of Cardiology* 2014;**172**:466-469. doi: 10.1016/j.ijcard.2013.12.230

27. Yu J, Zhou Z, McEvoy RD*, et al.* Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. *JAMA* 2017;**318**:156-166. doi: 10.1001/jama.2017.7967

28. Javaheri S, Martinez-Garcia MA, Campos-Rodriguez F. CPAP Treatment and Cardiovascular Prevention. *Chest* 2019;**156**:431-437. doi: 10.1016/j.chest.2019.04.092

29. Pack AI, Magalang UJ, Singh B*, et al.* Randomized clinical trials of cardiovascular disease in obstructive sleep apnea: understanding and overcoming bias. *Sleep* 2021;**44**. doi: 10.1093/sleep/zsaa229

30. Reynor A, McArdle N, Shenoy B*, et al.* Continuous positive airway pressure and adverse cardiovascular events in obstructive sleep apnea: are participants of randomized trials representative of sleep clinic patients? *Sleep* 2022;**45**. doi: 10.1093/sleep/zsab264

31. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. *Jama* 2020;**323**. doi: 10.1001/jama.2020.1166

32. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. *Contemporary Clinical Trials Communications* 2018;**11**:156-164. doi: 10.1016/j.conctc.2018.08.001

33. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology (Cambridge, Mass.)* 2000;**11**:550-560. doi: 10.1097/00001648-200009000-00011

34. Shi J, Norgeot B. Learning Causal Effects From Observational Data in Healthcare: A Review and Summary. *Frontiers in Medicine* 2022;**9**. doi: 10.3389/fmed.2022.864882

35. Reynor A, McArdle N, Shenoy B*, et al.* Continuous positive airway pressure and adverse cardiovascular events in obstructive sleep apnea: Are participants of randomized trials representative of sleep clinic patients? *Sleep* 2021. doi: 10.1093/sleep/zsab264

36. Pépin J-L, Bailly S, Rinder P*, et al.* Relationship Between CPAP Termination and All-Cause Mortality. *Chest* 2022;**161**:1657-1665. doi: 10.1016/j.chest.2022.02.013

37. Wickwire EM, Tom SE, Vadlamani A*, et al.* Older adult US Medicare beneficiaries with untreated obstructive sleep apnea are heavier users of health care than matched control patients. *Journal of Clinical Sleep Medicine* 2020;**16**:81-89. doi: 10.5664/jcsm.8128

38. Wickwire EM, Bailey MD, Somers VK*, et al.* CPAP adherence is associated with reduced risk for stroke among older adult Medicare beneficiaries with obstructive sleep apnea. *Journal of Clinical Sleep Medicine* 2021;**17**:1249-1255. doi: 10.5664/jcsm.9176

39. Bock JM, Needham KA, Gregory DA*, et al.* Continuous Positive Airway Pressure Adherence and Treatment Cost in Patients With Obstructive Sleep Apnea and Cardiovascular Disease. *Mayo Clinic Proceedings: Innovations, Quality & Outcomes* 2022;**6**:166-175. doi: 10.1016/j.mayocpiqo.2022.01.002

40. Waitman LR, Song X, Walpitage DL*, et al.* Enhancing PCORnet Clinical Research Network data completeness by integrating multistate insurance claims with electronic health records in a cloud environment aligned with CMS security and privacy requirements. *J Am Med Inform Assoc* 2021. doi: 10.1093/jamia/ocab269

41. Keenan BT, Kirchner HL, Veatch OJ*, et al.* Multisite validation of a simple electronic health record algorithm for identifying diagnosed obstructive sleep apnea. *J Clin Sleep Med* 2020;**16**:175-183. doi: 10.5664/jcsm.8160

42. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival Bias Associated with Time-to-Treatment Initiation in Drug Effectiveness Evaluation: A Comparison of Methods. *American Journal of Epidemiology* 2005;**162**:1016-1023. doi: 10.1093/aje/kwi307

43. Scharf MT, Keenan BT, Pack AI, Kuna ST. Mask Refills as a Measure of PAP Adherence. *Journal of Clinical Sleep Medicine* 2017;**13**:1337-1344. doi: 10.5664/jcsm.6810

44. Bettega F, Leyrat C, Tamisier R*, et al.* Application of Inverse-Probability-of-Treatment Weighting to Estimate the Effect of Daytime Sleepiness in Patients with Obstructive Sleep Apnea. *Annals of the American Thoracic Society* 2022;**19**:1570-1580. doi: 10.1513/AnnalsATS.202109-1036OC

45. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Annals of Internal Medicine* 2017;**167**. doi: 10.7326/m16-2607

46. Schwab RJ, Badr SM, Epstein LJ*, et al.* An official American Thoracic Society statement: continuous positive airway pressure adherence tracking systems. The optimal monitoring strategies and outcome measures in adults. *Am J Respir Crit Care Med* 2013;**188**:613-620. doi: 710.1164/rccm.201307-1282ST

47. Billings ME. Regional differences in PAP care: more questions than answers. *Journal of Clinical Sleep Medicine* 2021;**17**:363-364. doi: 10.5664/jcsm.9106

48. Patel N, Sam A, Valentin A, Quan SF, Parthasarathy S. Refill Rates of Accessories for Positive Airway Pressure Therapy as a Surrogate Measure of Long-Term Adherence. *Journal of Clinical Sleep Medicine* 2012;**08**:169-175. doi: 10.5664/jcsm.1772

49. Hu X, Fan J, Chen S, Yin Y, Zrenner B. The role of continuous positive airway pressure in blood pressure control for patients with obstructive sleep apnea and hypertension: a meta-analysis of randomized controlled trials. *J Clin Hypertens (Greenwich)* 2015;**17**:215-222. doi: 10.1111/jch.12472

50.	Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. *JAMA* 2015;**314**:2280-2293. doi: 10.1001/jama.2015.16303

51.	Liu L, Cao Q, Guo Z, Dai Q. Continuous Positive Airway Pressure in Patients With Obstructive Sleep Apnea and Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials. *J Clin Hypertens (Greenwich)* 2016;**18**:153-158. doi: 10.1111/jch.12639

52.	Tung P, Levitzky YS, Wang R*, et al.* Obstructive and Central Sleep Apnea and the Risk of Incident Atrial Fibrillation in a Community Cohort of Men and Women. *J Am Heart Assoc* 2017;**6**. doi: 10.1161/JAHA.116.004500

53.	Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005;**365**:1046-1053. doi: S0140-6736(05)71141-7 [pii]

10.1016/S0140-6736(05)71141-7

54.	Javaheri S, Barbe F, Campos-Rodriguez F*, et al.* Sleep Apnea. *Journal of the American College of Cardiology* 2017;**69**:841-858. doi: 10.1016/j.jacc.2016.11.069

55.	Drager LF, McEvoy RD, Barbe F*, et al.* Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science. *Circulation* 2017;**136**:1840-1850. doi: 10.1161/CIRCULATIONAHA.117.029400

56.	Campos-Rodriguez F, Queipo-Corona C, Carmona-Bernal C*, et al.* Continuous Positive Airway Pressure Improves Quality of Life in Women with Obstructive Sleep Apnea. A Randomized Controlled Trial. *Am J Respir Crit Care Med* 2016;**194**:1286-1294. doi: 10.1164/rccm.201602-0265OC

57.	Engleman HM, Cheshire KE, Deary IJ, Douglas NJ. Daytime sleepiness, cognitive performance and mood after continuous positive airway pressure for the sleep apnoea/hypopnoea syndrome. *Thorax* 1993;**48**:911-914. doi: 10.1136/thx.48.9.911

58.	Lyons OD, Ryan CM. Sleep Apnea and Stroke. *Can J Cardiol* 2015;**31**:918-927. doi: 10.1016/j.cjca.2015.03.014

59.	McEvoy RD, Antic NA, Heeley E*, et al.* CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. *N Engl J Med* 2016;**375**:919-931. doi: 10.1056/NEJMoa1606599

60.	Peker Y, Glantz H, Eulenburg C*, et al.* Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. *Am J Respir Crit Care Med* 2016;**194**:613-620. doi: 10.1164/rccm.201601-0088OC

61.	Sanchez-de-la-Torre M, Sanchez-de-la-Torre A, Bertran S*, et al.* Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. *Lancet Respir Med* 2020;**8**:359-367. doi: 10.1016/S2213-2600(19)30271-1

62.	Allen AJH, Jen R, Mazzotti DR*, et al.* Symptom subtypes and risk of incident cardiovascular and cerebrovascular disease in a clinic-based obstructive sleep apnea cohort. *J Clin Sleep Med* 2022. doi: 10.5664/jcsm.9986

63.	Wu B, Tarraf W, Wallace DM*, et al.* Cardiovascular correlates of sleep apnea phenotypes: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). *PLoS One* 2022;**17**:e0265151. doi: 10.1371/journal.pone.0265151

64.	Malhotra A, Sterling KL, Cistulli PA*, et al.* Dose-Response Relationship between Obstructive Sleep Apnea Therapy Adherence and Healthcare Utilization. *Annals of the American Thoracic Society* 2023;**20**:891-897. doi: 10.1513/AnnalsATS.202208-738OC

65.	Malhotra A, Cole KV, Malik AS*, et al.* Positive Airway Pressure Adherence and Health Care Resource Utilization in Patients With Obstructive Sleep Apnea and Heart Failure With

Reduced Ejection Fraction. *Journal of the American Heart Association* 2023;**12**. doi: 10.1161/jaha.122.028732

66. U.S. Department of Health and Human Services Agency for Healthcare Research and Quality. Long-Term Health Outcomes in Obstructive Sleep Apnea: A Systematic Review of Comparative Studies Evaluating Positive Airway Pressure and the Validity of Breathing Measures as Surrogate Outcomes. In; 2022.

67. Ponce S, Pastor E, Orosa B, *et al.* The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial. *European Respiratory Journal* 2019;**54**. doi: 10.1183/13993003.00518-2019

68. Martinez-Garcia MA, Oscullo G, Ponce S, *et al.* Effect of continuous positive airway pressure in very elderly with moderate-to-severe obstructive sleep apnea pooled results from two multicenter randomized controlled trials. *Sleep Medicine* 2022;**89**:71-77. doi: 10.1016/j.sleep.2021.11.009

69. Greenberg-Dotan S, Reuveni H, Simon-Tuval T, Oksenberg A, Tarasiuk A. Gender differences in morbidity and health care utilization among adult obstructive sleep apnea patients. *Sleep* 2007;**30**:1173-1180. doi: 10.1093/sleep/30.9.1173

70. Ayub S, Won CHJ. Obstructive Sleep Apnea in Women. *Journal of Sleep Medicine* 2019;**16**:75-80. doi: 10.13078/jsm.190047

71. Simon-Tuval T, Reuveni H, Greenberg-Dotan S, *et al.* Low Socioeconomic Status Is a Risk Factor for CPAP Acceptance Among Adult OSAS Patients Requiring Treatment. *Sleep* 2009;**32**:545-552. doi: 10.1093/sleep/32.4.545

72. Billings ME, Auckley D, Benca R, *et al.* Race and residential socioeconomics as predictors of CPAP adherence. *Sleep* 2011;**34**:1653-1658. doi: 10.5665/sleep.1428

73. May AM, Patel SR, Yamauchi M, *et al.* Moving toward Equitable Care for Sleep Apnea in the United States: Positive Airway Pressure Adherence Thresholds: An Official American Thoracic Society Policy Statement. *American Journal of Respiratory and Critical Care Medicine* 2023;**207**:244-254. doi: 10.1164/rccm.202210-1846ST

74. Dalmar A, Singh M, Heis Z, *et al.* Risk of Atrial Fibrillation and Stroke After Bariatric Surgery in Patients With Morbid Obesity With or Without Obstructive Sleep Apnea. *Stroke* 2021;**52**:2266-2274. doi: 10.1161/strokeaha.120.031920

75. Stewart NH, Walters RW, Mokhlesi B, Lauderdale DS, Arora VM. Sleep in hospitalized patients with chronic obstructive pulmonary disease: an observational study. *Journal of Clinical Sleep Medicine* 2020;**16**:1693-1699. doi: 10.5664/jcsm.8646

76. Protasiewicz Timofticiuc DC, Vladu IM, Ștefan A-G, *et al.* Associations of Chronic Diabetes Complications and Cardiovascular Risk with the Risk of Obstructive Sleep Apnea in Patients with Type 2 Diabetes. *Journal of Clinical Medicine* 2022;**11**. doi: 10.3390/jcm11154403

77. Pépin J-L, Bailly S, Rinder P, *et al.* CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. *Journal of Clinical Medicine* 2021;**10**. doi: 10.3390/jcm10050936

78. Pépin JL, Bailly S, Tamisier R. Big Data in sleep apnoea: Opportunities and challenges. *Respirology* 2019:resp.13669. doi: 10.1111/resp.13669

79. Wickwire EM, Bailey MD, Somers VK, *et al.* CPAP adherence is associated with reduced inpatient utilization among older adult Medicare beneficiaries with pre-existing cardiovascular disease. *Journal of Clinical Sleep Medicine* 2022;**18**:39-45. doi: 10.5664/jcsm.9478

80. Mokhlesi B, Punjabi NM. "REM-related" Obstructive Sleep Apnea: An Epiphenomenon or a Clinically Important Entity? *Sleep* 2012;**35**:5-7. doi: 10.5665/sleep.1570

81. Varga AW, Mokhlesi B. REM obstructive sleep apnea: risk for adverse health outcomes and novel treatments. *Sleep and Breathing* 2018;**23**:413-423. doi: 10.1007/s11325-018-1727-2

82. Kapur VK, Psaty BM. Obtaining Valid Estimates of the Effect of CPAP Therapy. *Chest* 2022;**161**:1444-1445. doi: 10.1016/j.chest.2022.03.027

Figure Legends

Figure 1. Overview of the PAP initiation analysis study design.

Figure 2. Overview of the PAP utilisation exposure group study design.

Figure 3. Study cohort definitions and CONSORT diagram.

Figure 4: Unadjusted and adjusted Kaplan-Meier survival curves describing the survival

probabilities between PAP initiation exposure groups and all-cause mortality (top) and MACE

(bottom). Numbers in boxes represent annual survival probabilities per group. The results of log-

rank tests comparing exposure groups are also shown.

Figure 5. Summary of IPTW-adjusted Cox proportional hazards models assessing the effect of

PAP initiation on all-cause mortality (ACM) and MACE in all eligible participants (Stratification:

None) and within categories of relevant sociodemographic and clinical characteristics. Results

were derived from IPTW-weighted Cox proportional hazards models adjusted for age, sex, race,

low-income-subsidy or dual-eligibility indicator, type 2 diabetes, hypertension, obesity, MACE

(all-cause mortality only), COPD, hypersomnia, and insomnia. Among stratified models,

stratification variable was not included as a covariate in propensity score models nor in outcome

models. Reference category is no evidence of PAP initiation. Abbreviations: ACM: all-cause

mortality; COPD: chronic obstructive pulmonary disease; PAP: positive airway pressure; HR:

hazard ratio; CI: confidence interval; MACE: major adverse cardiovascular event; IPTW: inverse

probability of treatment weights.

Figure 6. Summary of IPTW-adjusted Cox proportional hazards models assessing the effect of

PAP utilisation exposure groups based on quartiles of PAP claim counts on all-cause mortality

(ACM) and MACE among all participants and stratified by sociodemographic variables. PAP

exposure groups were defined as follows: Q1 (reference): 1-11 claims; Q2: 12-14 claims; Q3:

15-16 claims; Q4: >16 claims). Results were derived from IPTW-weighted Cox proportional

hazards models adjusted for age, sex, race, low-income-subsidy or dual-eligibility indicator, type

2 diabetes, hypertension, obesity, MACE (all-cause mortality only), COPD, hypersomnia, and

insomnia. Among stratified models, stratification variable was not included as a covariate in

propensity score models nor in outcome models. Abbreviations: ACM: all-cause mortality;

COPD: chronic obstructive pulmonary disease; PAP: positive airway pressure; HR: hazard ratio;

CI: confidence interval; MACE: major adverse cardiovascular event; IPTW: inverse probability of

treatment weights.

Figure 7. Summary of IPTW-adjusted Cox proportional hazards models assessing the effect of

PAP utilisation exposure groups based on quartiles of PAP claim counts on all-cause mortality

(ACM) and MACE stratified by comorbidities. PAP exposure groups were defined as follows: Q1

(reference): 1-11 claims; Q2: 12-14 claims; Q3: 15-16 claims; Q4: >16 claims). Results were

derived from IPTW-weighted Cox proportional hazards models adjusted for age, sex, race, low-

income-subsidy or dual-eligibility indicator, type 2 diabetes, hypertension, obesity, MACE (all-

cause mortality only), COPD, hypersomnia, and insomnia. Among stratified models,

stratification variable was not included as a covariate in propensity score models nor in outcome

models. Abbreviations: ACM: all-cause mortality; COPD: chronic obstructive pulmonary disease;

PAP: positive airway pressure; HR: hazard ratio; CI: confidence interval; MACE: major adverse

cardiovascular event; IPTW: inverse probability of treatment weights.

Stratification	ACM...	ACM.HR (95% CI)	MACE...	MACE.HR (95% CI)
01.None				
		0.57 (0.56–0.59) ****		0.90 (0.88–0.92) ****
02.Age				
65–69 years		0.69 (0.65–0.73) ****		0.97 (0.94–1.00)
70–74 years		0.58 (0.56–0.60) ****		0.89 (0.87–0.91) ****
75–79 years		0.56 (0.54–0.58) ****		0.89 (0.87–0.92) ****
80+ years		0.55 (0.54–0.57) ****		0.87 (0.85–0.89) ****
03.Sex				
Female		0.55 (0.54–0.57) ****		0.88 (0.86–0.90) ****
Male		0.59 (0.57–0.60) ****		0.92 (0.90–0.93) ****
04.Race				
Black		0.55 (0.50–0.59) ****		0.92 (0.86–0.99) *
Native American		0.68 (0.48–0.96)		1.07 (0.83–1.38)
Asian		0.58 (0.46–0.74) ***		1.02 (0.87–1.21)
Other		0.62 (0.43–0.88) *		1.04 (0.84–1.29)
Unknown		0.58 (0.54–0.63) ****		0.95 (0.90–1.01)
White		0.57 (0.56–0.59) ****		0.89 (0.88–0.91) ****
05.Low–income–subsidy/DUal Eligibility				
No		0.59 (0.57–0.60) ****		0.92 (0.91–0.94) ****
Yes		0.55 (0.54–0.57) ****		0.85 (0.83–0.87) ****
06.Obesity				
No		0.60 (0.59–0.61) ****		0.91 (0.90–0.93) ****
Yes		0.52 (0.50–0.53) ****		0.86 (0.83–0.88) ****
07.COPD History				
No		0.57 (0.56–0.58) ****		0.91 (0.90–0.92) ****
Yes		0.58 (0.56–0.59) ****		0.87 (0.85–0.90) ****
08.Hypertension History				
No		0.63 (0.59–0.68) ****		0.88 (0.85–0.91) ****
Yes		0.57 (0.56–0.58) ****		0.90 (0.89–0.92) ****
09.T2DM History				
No		0.59 (0.57–0.60) ****		0.90 (0.89–0.92) ****
Yes		0.56 (0.55–0.58) ****		0.90 (0.88–0.91) ****
10.MACE History				
No		0.61 (0.59–0.63) ****		0.90 (0.89–0.91) ****
Yes		0.55 (0.54–0.57) ****		
11.Hypersomnia				
No		0.57 (0.56–0.58) ****		0.90 (0.89–0.91) ****
Yes		0.69 (0.62–0.76) ****		0.89 (0.84–0.95) **
12.Insomina				
No		0.57 (0.56–0.59) ****		0.90 (0.89–0.91) ****
Yes		0.56 (0.53–0.59) ****		0.89 (0.85–0.93) ****

ACM: 0.1 0.5 1 1.2 HR Better ← → Worse

MACE: 0.1 0.5 1 1.2 HR Better ← → Worse

Stratification	ACM...	ACM.HR (95% CI)	MACE...	MACE.HR (95% CI)
01.None:				
Q2 (12 – 14)		0.80 (0.78–0.83) ****		0.91 (0.89–0.93) ***
Q3 (15 – 16)		0.68 (0.65–0.70) ****		0.87 (0.84–0.89) ****
Q4 (> 16)		0.65 (0.63–0.68) ****		0.85 (0.83–0.88) ****
02.Age:65–69 years				
Q2 (12 – 14)		0.71 (0.65–0.78) ****		0.87 (0.83–0.91) **
Q3 (15 – 16)		0.59 (0.53–0.65) ****		0.79 (0.74–0.84) ****
Q4 (> 16)		0.57 (0.51–0.63) ****		0.81 (0.76–0.86) ****
02.Age:70–74 years				
Q2 (12 – 14)		0.85 (0.80–0.91) **		0.88 (0.85–0.92) **
Q3 (15 – 16)		0.71 (0.66–0.76) ****		0.87 (0.83–0.92) ****
Q4 (> 16)		0.68 (0.63–0.73) ****		0.87 (0.83–0.91) ****
02.Age:75–79 years				
Q2 (12 – 14)		0.77 (0.72–0.82) ****		0.94 (0.89–0.99)
Q3 (15 – 16)		0.63 (0.58–0.68) ****		0.93 (0.88–1.00)
Q4 (> 16)		0.65 (0.60–0.70) ****		0.86 (0.81–0.92) **
02.Age:80+ years				
Q2 (12 – 14)		0.82 (0.78–0.87) ****		0.99 (0.93–1.04)
Q3 (15 – 16)		0.73 (0.68–0.77) ****		0.90 (0.85–0.96) *
Q4 (> 16)		0.68 (0.64–0.73) ****		0.89 (0.83–0.95) *
03.Sex:Female				
Q2 (12 – 14)		0.83 (0.78–0.87) ****		0.89 (0.86–0.93) **
Q3 (15 – 16)		0.72 (0.68–0.77) ****		0.85 (0.82–0.89) ****
Q4 (> 16)		0.64 (0.60–0.68) ****		0.80 (0.77–0.84) ****
03.Sex:Male				
Q2 (12 – 14)		0.79 (0.76–0.83) ****		0.92 (0.89–0.95) *
Q3 (15 – 16)		0.65 (0.62–0.68) ****		0.87 (0.84–0.91) ****
Q4 (> 16)		0.66 (0.63–0.69) ****		0.89 (0.85–0.92) ****
04.Race:Asian				
Q2 (12 – 14)		0.69 (0.42–1.15)		1.08 (0.73–1.59)
Q3 (15 – 16)		0.42 (0.24–0.73) *		1.21 (0.80–1.81)
Q4 (> 16)		0.36 (0.18–0.71) *		1.18 (0.78–1.80)
04.Race:Black				
Q2 (12 – 14)		0.80 (0.67–0.97)		1.32 (1.13–1.55) *
Q3 (15 – 16)		0.67 (0.55–0.82) **		1.15 (0.97–1.36)
Q4 (> 16)		0.63 (0.52–0.77) **		0.84 (0.71–1.00)
04.Race:Native American				
Q2 (12 – 14)		2.17 (0.78–6.02)		0.30 (0.15–0.60) *
Q3 (15 – 16)		0.45 (0.17–1.21)		0.34 (0.18–0.67)
Q4 (> 16)		0.87 (0.32–2.39)		0.34 (0.18–0.64) *
04.Race:Other				
Q2 (12 – 14)		0.28 (0.12–0.63) *		1.76 (1.06–2.91)
Q3 (15 – 16)		0.42 (0.20–0.88)		1.84 (1.08–3.14)
Q4 (> 16)		0.59 (0.30–1.15)		1.24 (0.70–2.20)
04.Race:Unknown				
Q2 (12 – 14)		0.96 (0.81–1.14)		0.88 (0.77–1.01)
Q3 (15 – 16)		0.89 (0.74–1.06)		0.80 (0.69–0.93) *
Q4 (> 16)		0.86 (0.73–1.02)		0.83 (0.73–0.95)
04.Race:White				
Q2 (12 – 14)		0.80 (0.77–0.83) ****		0.90 (0.88–0.92) ***
Q3 (15 – 16)		0.67 (0.65–0.70) ****		0.86 (0.83–0.88) ****
Q4 (> 16)		0.65 (0.62–0.67) ****		0.86 (0.84–0.89) ****
05.Low-income-subsidy/Dual Eligibility:No				
Q2 (12 – 14)		0.82 (0.79–0.86) ****		0.94 (0.91–0.96) *
Q3 (15 – 16)		0.70 (0.67–0.74) ****		0.88 (0.85–0.91) ****
Q4 (> 16)		0.66 (0.63–0.70) ****		0.87 (0.84–0.90) ****
05.Low-income-subsidy/Dual Eligibility:Yes				
Q2 (12 – 14)		0.76 (0.72–0.81) ****		0.84 (0.80–0.88) ****
Q3 (15 – 16)		0.63 (0.59–0.68) ****		0.83 (0.79–0.88) ****
Q4 (> 16)		0.63 (0.59–0.67) ****		0.80 (0.76–0.85) ****

ACM axis: 0.1 0.5 1 1.2 HR — Better ← → Worse

MACE axis: 0.1 0.5 1 1.2 HR — Better ← → Worse

Stratification	ACM...	ACM.HR (95% CI)	MACE...	MACE.HR (95% CI)
06.Obesity:No				
Q2 (12 – 14)		0.75 (0.72–0.78) ****		0.92 (0.90–0.95) **
Q3 (15 – 16)		0.66 (0.63–0.70) ****		0.88 (0.85–0.91) ****
Q4 (> 16)		0.62 (0.59–0.65) ****		0.84 (0.81–0.87) ****
06.Obesity:Yes				
Q2 (12 – 14)		0.90 (0.85–0.95) *		0.89 (0.86–0.93) **
Q3 (15 – 16)		0.71 (0.66–0.75) ****		0.84 (0.80–0.88) ****
Q4 (> 16)		0.71 (0.67–0.75) ****		0.87 (0.83–0.91) ***
07.COPD History:No				
Q2 (12 – 14)		0.78 (0.75–0.81) ****		0.91 (0.89–0.93) ***
Q3 (15 – 16)		0.68 (0.65–0.71) ****		0.87 (0.85–0.90) ****
Q4 (> 16)		0.66 (0.63–0.69) ****		0.85 (0.82–0.88) ****
07.COPD History:Yes				
Q2 (12 – 14)		0.85 (0.80–0.91) **		0.90 (0.84–0.96)
Q3 (15 – 16)		0.68 (0.63–0.73) ****		0.84 (0.77–0.91) **
Q4 (> 16)		0.64 (0.60–0.69) ****		0.86 (0.80–0.94) *
08.Hypertension History:No				
Q2 (12 – 14)		0.64 (0.56–0.74) ***		0.82 (0.75–0.89) *
Q3 (15 – 16)		0.58 (0.49–0.68) ****		0.81 (0.74–0.90) **
Q4 (> 16)		0.53 (0.45–0.62) ****		0.75 (0.68–0.83) ***
08.Hypertension History:Yes				
Q2 (12 – 14)		0.81 (0.79–0.84) ****		0.92 (0.90–0.94) ***
Q3 (15 – 16)		0.69 (0.66–0.71) ****		0.87 (0.85–0.90) ****
Q4 (> 16)		0.66 (0.64–0.69) ****		0.86 (0.84–0.89) ****
09.T2DM History:No				
Q2 (12 – 14)		0.74 (0.71–0.78) ****		0.91 (0.89–0.94) ***
Q3 (15 – 16)		0.62 (0.58–0.65) ****		0.87 (0.84–0.90) ****
Q4 (> 16)		0.63 (0.59–0.66) ****		0.86 (0.83–0.90) ****
09.T2DM History:Yes				
Q2 (12 – 14)		0.87 (0.83–0.91) ***		0.91 (0.87–0.94) **
Q3 (15 – 16)		0.75 (0.71–0.79) ****		0.86 (0.82–0.90) ****
Q4 (> 16)		0.69 (0.65–0.72) ****		0.84 (0.81–0.88) ****
10.MACE History:No				
Q2 (12 – 14)		0.69 (0.66–0.73) ****		0.91 (0.89–0.93) ***
Q3 (15 – 16)		0.63 (0.59–0.67) ****		0.87 (0.84–0.89) ****
Q4 (> 16)		0.64 (0.61–0.68) ****		0.85 (0.83–0.88) ****
10.MACE History:Yes				
Q2 (12 – 14)		0.88 (0.85–0.92) ***		
Q3 (15 – 16)		0.72 (0.68–0.75) ****		
Q4 (> 16)		0.67 (0.64–0.71) ****		
11.Hypersomnia:No				
Q2 (12 – 14)		0.80 (0.77–0.83) ****		0.91 (0.89–0.93) ***
Q3 (15 – 16)		0.68 (0.65–0.70) ****		0.86 (0.84–0.89) ****
Q4 (> 16)		0.65 (0.63–0.68) ****		0.85 (0.82–0.87) ****
11.Hypersomnia:Yes				
Q2 (12 – 14)		1.14 (0.76–1.71)		1.80 (1.30–2.49)
Q3 (15 – 16)		1.02 (0.66–1.57)		1.24 (0.82–1.86)
Q4 (> 16)		0.65 (0.40–1.04)		1.61 (1.11–2.32)
12.Insomina:No				
Q2 (12 – 14)		0.81 (0.79–0.84) ****		0.92 (0.90–0.94) ***
Q3 (15 – 16)		0.69 (0.66–0.71) ****		0.86 (0.84–0.89) ****
Q4 (> 16)		0.67 (0.64–0.69) ****		0.84 (0.82–0.87) ****
12.Insomina:Yes				
Q2 (12 – 14)		0.69 (0.61–0.79) ***		0.86 (0.78–0.95)
Q3 (15 – 16)		0.54 (0.46–0.63) ****		0.97 (0.86–1.10)
Q4 (> 16)		0.46 (0.39–0.54) ****		0.98 (0.87–1.11)

ACM: 0.1 0.5 1 1.2 HR Better ← → Worse

MACE: 0.1 0.5 1 1.2 HR Better ← → Worse